ES2548327T3 - Método para detectar proBNP con un anticuerpo monoclonal - Google Patents

Método para detectar proBNP con un anticuerpo monoclonal Download PDF

Info

Publication number
ES2548327T3
ES2548327T3 ES10172014.2T ES10172014T ES2548327T3 ES 2548327 T3 ES2548327 T3 ES 2548327T3 ES 10172014 T ES10172014 T ES 10172014T ES 2548327 T3 ES2548327 T3 ES 2548327T3
Authority
ES
Spain
Prior art keywords
probnp
monoclonal antibody
antibody
determined
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10172014.2T
Other languages
English (en)
Inventor
Volker Klemt
Anneliese Borgya
Andreas Gallusser
Michael Grol
Christoph Seidel
Klaus Hallermayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33427054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2548327(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2548327T3 publication Critical patent/ES2548327T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo que se fija específicamente al proBNP nativo, en el cual dicho anticuerpo que se fija específicamente al proBNP nativo es un anticuerpo monoclonal el cual se fija a péptidos sintéticos que consisten en los aminoácidos 39 a 46, 40 a 47, 41 a 48 y 42 a 49, respectivamente, de NT-proBNP y en términos de los valores de proBNP, como se determinan en muestras de pacientes que usan dicho anticuerpo se correlacionan con un valor r de al menos r>=0,95 o superior a los valores de proBNP como se determina en dichas muestras usando el anticuerpo monoclonal MAB 1.21.3 producido por la línea celular de hibridoma depositada bajo DSM ACC2650 en la DSMZ, y en el cual dicho valor r se determina mediante análisis de regresión lineal.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
ES10172014.2T 2003-05-12 2004-05-12 Método para detectar proBNP con un anticuerpo monoclonal Expired - Lifetime ES2548327T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010591 2003-05-12
EP03010591 2003-05-12

Publications (1)

Publication Number Publication Date
ES2548327T3 true ES2548327T3 (es) 2015-10-15

Family

ID=33427054

Family Applications (3)

Application Number Title Priority Date Filing Date
ES04732278T Expired - Lifetime ES2372282T3 (es) 2003-05-12 2004-05-12 Método para detectar probnp con un anticuerpo monoclonal que fija los aminoácidos 38-43.
ES04732282T Expired - Lifetime ES2369008T3 (es) 2003-05-12 2004-05-12 Método para detectar probnp con un anticuerpo monoclonal que fija los aminoácidos 42-46.
ES10172014.2T Expired - Lifetime ES2548327T3 (es) 2003-05-12 2004-05-12 Método para detectar proBNP con un anticuerpo monoclonal

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES04732278T Expired - Lifetime ES2372282T3 (es) 2003-05-12 2004-05-12 Método para detectar probnp con un anticuerpo monoclonal que fija los aminoácidos 38-43.
ES04732282T Expired - Lifetime ES2369008T3 (es) 2003-05-12 2004-05-12 Método para detectar probnp con un anticuerpo monoclonal que fija los aminoácidos 42-46.

Country Status (16)

Country Link
US (4) US7264939B2 (es)
EP (4) EP2949669A1 (es)
JP (4) JP5128125B2 (es)
KR (2) KR100857752B1 (es)
CN (3) CN100497393C (es)
AT (2) ATE522546T1 (es)
AU (1) AU2004235974B2 (es)
BR (1) BRPI0410261B8 (es)
CA (2) CA2522378C (es)
DK (3) DK2256132T3 (es)
ES (3) ES2372282T3 (es)
HK (1) HK1097855A1 (es)
HU (1) HUE025169T2 (es)
MX (1) MXPA05011826A (es)
PL (3) PL2256132T3 (es)
WO (2) WO2004099252A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843396B1 (fr) * 2002-08-07 2005-04-15 Bio Rad Pasteur Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
HUE025169T2 (en) * 2003-05-12 2016-02-29 Hoffmann La Roche A method for detecting proBNP with a monoclonal antibody
US20070037208A1 (en) * 2003-05-29 2007-02-15 Foote Robert S Method for detecting cardiac ischemia via changes in b-natriuretic peptide levels
DE10355731A1 (de) 2003-11-28 2005-06-30 Roche Diagnostics Gmbh Analytischer Sandwichtest zur Bestimmung von NT-proBNP
DE602005001299T2 (de) * 2004-07-07 2008-02-07 Roche Diagnostics Gmbh Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
DK2115477T3 (en) 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
KR100836322B1 (ko) * 2007-08-31 2008-06-09 현대자동차주식회사 차량용 흡음재 제작장치 및 방법
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
JP5524182B2 (ja) 2008-04-30 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｓｆｒｐ−３の使用
CN102549436A (zh) 2009-07-27 2012-07-04 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途
WO2011060361A1 (en) * 2009-11-13 2011-05-19 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
CA2807240A1 (en) 2010-08-04 2012-02-09 Idexx Laboratories, Inc. Detection of degradation products of canine nt-probnp
US8481333B2 (en) 2011-05-31 2013-07-09 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
WO2013042603A1 (ja) * 2011-09-20 2013-03-28 コニカミノルタホールディングス株式会社 検体希釈用液、それを用いたキットおよび蛍光測定方法
US20140273273A1 (en) 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
CN103304665A (zh) * 2013-05-21 2013-09-18 上海贝西生物科技有限公司 一种抗氨基末端脑利钠肽前体单克隆抗体及其应用
WO2016056664A1 (ja) * 2014-10-10 2016-04-14 松森　昭 心不全患者の検出方法、心疾患の識別方法、心不全の検査試薬、心不全の検査キット、心不全を検出するための装置及び心不全を検出するためのプログラム
EP3360570A1 (en) 2017-02-13 2018-08-15 Roche Diagnostics GmbH Antibodies recognizing genetic variants
US11549940B2 (en) 2017-10-02 2023-01-10 Otsuka Pharmaceutical Co., Ltd. Method for detecting analyte
EP3779438A4 (en) * 2018-04-13 2022-01-26 Kyoritsu Seiyaku Corporation PROCEDURE FOR DETECTING HEART FAILURE, INSTRUMENT FOR DETECTING HEART FAILURE, SANDWICH IMMUNOASSAY PROCEDURE AND ANTIBODY COMBINATION
CN108752480B (zh) * 2018-05-30 2022-03-29 中元汇吉生物技术股份有限公司 一种免疫原组合物、其制备方法及其用途
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
CN111487222B (zh) * 2019-01-28 2023-11-14 上海乐合生物科技有限公司 一种检测bnp的spr芯片的制备方法
CN114207444A (zh) 2019-08-13 2022-03-18 挪威金田有限公司 用于NT-proBNP定量的高灵敏度颗粒增强测定
EP4222499A1 (en) * 2020-09-30 2023-08-09 F. Hoffmann-La Roche AG Circulating total-nt-probnp (glycosylated and unglycosylated nt-probnp) and its ratio with nt-probnp (unglycosylated nt-probnp) in the assessment of atrial fibrillation
CN112964885B (zh) * 2021-02-20 2022-11-11 广东菲鹏生物有限公司 一种氨基末端脑尿钠肽检测方法和试剂盒
CN112986586A (zh) * 2021-02-20 2021-06-18 广东菲鹏生物有限公司 一种氨基末端脑尿钠肽检测方法和试剂盒
WO2023052642A1 (en) 2021-10-01 2023-04-06 Gentian As Novel method for determining a concentration of n-terminal pro-hormone bnp (nt-probnp) in a sample
WO2023175176A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Cmybpc marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction
WO2023175152A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3445816C1 (de) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flaechenfoermiges diagnostisches Mittel
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
IL144062A0 (en) 1999-01-29 2002-04-21 Roche Diagnostics Gmbh METHOD OF IDENTIFYING N-TERMINAL proBNP
US20030219734A1 (en) 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US20040096919A1 (en) * 2002-11-18 2004-05-20 Michelle Davey Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP
HUE025169T2 (en) * 2003-05-12 2016-02-29 Hoffmann La Roche A method for detecting proBNP with a monoclonal antibody

Also Published As

Publication number Publication date
JP5649631B2 (ja) 2015-01-07
BRPI0410261A (pt) 2006-05-16
HUE025169T2 (en) 2016-02-29
JP5128125B2 (ja) 2013-01-23
CN1832964A (zh) 2006-09-13
EP1625163B1 (en) 2011-08-31
EP2256132B1 (en) 2015-04-01
KR100857752B1 (ko) 2008-09-11
US20070099241A1 (en) 2007-05-03
CA2522747C (en) 2012-08-14
US7807380B2 (en) 2010-10-05
JP2007535470A (ja) 2007-12-06
BRPI0410261B8 (pt) 2021-07-27
JP2007525427A (ja) 2007-09-06
US7264938B2 (en) 2007-09-04
US20070117156A1 (en) 2007-05-24
ES2369008T3 (es) 2011-11-24
ES2372282T3 (es) 2012-01-18
ATE517124T1 (de) 2011-08-15
KR20060003905A (ko) 2006-01-11
JP4430066B2 (ja) 2010-03-10
CA2522378A1 (en) 2004-11-18
PL1625163T3 (pl) 2012-01-31
CA2522747A1 (en) 2004-11-18
JP4834136B2 (ja) 2011-12-14
EP2256132A1 (en) 2010-12-01
EP1625164B1 (en) 2011-07-20
PL1625164T3 (pl) 2011-12-30
PL2256132T3 (pl) 2016-08-31
BRPI0410261B1 (pt) 2020-03-10
CN100497393C (zh) 2009-06-10
EP1625163A1 (en) 2006-02-15
EP1625164A1 (en) 2006-02-15
MXPA05011826A (es) 2006-01-26
US20060110775A1 (en) 2006-05-25
US7811770B2 (en) 2010-10-12
AU2004235974B2 (en) 2008-02-14
HK1097855A1 (en) 2007-07-06
EP1625163B8 (en) 2011-11-02
WO2004099253A1 (en) 2004-11-18
EP2949669A1 (en) 2015-12-02
CN1784425A (zh) 2006-06-07
CN101967190A (zh) 2011-02-09
US7264939B2 (en) 2007-09-04
JP2013018784A (ja) 2013-01-31
JP2010011860A (ja) 2010-01-21
US20060110776A1 (en) 2006-05-25
DK1625163T3 (da) 2011-12-05
ATE522546T1 (de) 2011-09-15
DK2256132T3 (en) 2015-07-13
CA2522378C (en) 2011-03-29
WO2004099252A1 (en) 2004-11-18
KR20080011467A (ko) 2008-02-04
DK1625164T3 (da) 2011-10-31
AU2004235974A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
ES2548327T3 (es) Método para detectar proBNP con un anticuerpo monoclonal
ES2487846T3 (es) Anticuerpos anti-hepcindina y métodos de uso
ES2523837T3 (es) Agentes de unión específica al factor de crecimiento de hepatocitos
ATE178097T1 (de) Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen
PE20090722A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
ATE487946T1 (de) Analytischer sandwichtest zur bestimmung von nt- probnp
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
RU2019101062A (ru) Способ получения антител против амн и их применение
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
WO2015138907A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
RS52804B (en) HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE
RS53291B (en) BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CO5611164A2 (es) Anticuerpos humanizados que reconocen el pepetido amiloide beta
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
DE60334696D1 (de) Antikörper, die spezifische für probnp(1-108) sind, und ihre verwendung zur diagnose von herzinfarkt
ATE395364T1 (de) Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
ATE335763T1 (de) Sandwich-immunoassay zur bestimmung von proanp- teilpeptiden
CL2008003587A1 (es) Polipeptido que comprende un epitope inductor de la muerte celular; metodo de produccion de anticuerpos; metodo de identificacion de un compuesto candidato para inducir la muerte de las celulas t activadas. (divisional solicitud n° 1082-05)
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
ATE360034T1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
ES2535426T3 (es) Anticuerpos anti-TNFα y métodos de uso
EP1245957A3 (en) Method of measuring ceruloplasmin concentration with enzyme-linked immunosorbent assay or dissociation-enhanced time-resolved fluoroimmunoassay in a blood spot, and Wilson's disease screening kit and method of diagnosing Wilson's disease